Quidel Corp (QDEL) Tops Q4 EPS by 20c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Quidel Reports Fourth Quarter and Full Year 2018 Financial Results
February 13, 2019 4:10 PM ESTSAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and year ended December31, 2018.
Fourth Quarter 2018 Highlights:
Total revenue grew 15% to $132.6 million as compared to $114.9 million in the fourth quarter of 2017. Quidels legacy revenue grew 3% from the fourth quarter of 2017 to $69.6 million. Total influenza revenue increased 4% from the fourth quarter of 2017 to $34.9 million. Cardiac Immunoassay revenue grew 34% from the fourth... More